SER 109
Alternative Names: LIVE-BRPK - Seres Therapeutics; SER-109; VOWSTLatest Information Update: 07 Oct 2024
At a glance
- Originator Seres Health
- Developer Seres Therapeutics
- Class Bacteria
- Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Clostridium difficile infections
Most Recent Events
- 30 Sep 2024 Seres Therapeutics completes SER 109 asset sale to Nestle Health Science
- 06 Jun 2024 Nestlé Health Science plans to complete the purchase of SER 109 from Seres Therapeutics by September 2024
- 18 May 2024 Updated adverse event data from the phase III ECOSPOR IV trial in Clostridium difficile infections presented at the Digestive Disease Week (DDW-2024)